Radioligand Therapy
•19 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (19)
%
| Company | Market Cap | Price |
|---|---|---|
|
Radioligand Therapy is a key platform with Pluvicto and expanding pipelines.
|
$252.00B |
$130.00
|
|
AlphaMedix is a radioligand therapy, a distinct radiopharmaceutical modality.
|
$120.19B |
$98.46
|
|
Radiopharmaceutical Therapeutics (e.g., RayzeBio collaboration/licensing) represents a new modality in the pipeline.
|
$89.46B |
$43.96
-1.83%
|
|
Pipeline includes radioligand therapy/theranostic assets; radiopharmaceutical therapy is a key investable theme for the company.
|
$3.68B |
$53.23
+2.54%
|
|
Telix's core offering includes radioligand therapies using radiopharmaceuticals for cancer (alpha-emitter and related therapies).
|
$3.35B |
$10.00
|
|
Radioligand Therapies (RLTs) are a key modality pursued by Immunome (e.g., IM-3050) representing a distinct investable cancer-therapy category.
|
$1.21B |
$13.92
-5.18%
|
|
Radioligand Therapy: radiopharmaceutical isotopes used for targeted cancer therapies.
|
$760.38M |
$10.13
+14.21%
|
|
BRC constructs enable radioligand therapy concepts, delivering radioactivity to tumors.
|
$576.19M |
$8.32
-7.25%
|
|
Radioligand therapy applications using Lu-177 and Ac-225 conjugates within MNPR-101.
|
$537.04M |
$87.82
-14.34%
|
|
Radioligand therapy approach via the SADA PRIT platform.
|
$389.89M |
$8.61
|
|
Strategic focus on radioligand therapy and alpha-emitting radiopharmaceuticals (Lead-212) for cancer.
|
$360.75M |
$4.86
+15.71%
|
|
TOI plans to deploy Radiopharmaceutical Therapy (radioligand therapy) as part of its oncology care offering, representing a distinct therapeutic modality and revenue stream.
|
$338.20M |
$3.79
-4.05%
|
|
MP0712 is a Radio-DARPin therapy targeting DLL3 for SCLC, a radioligand therapy program.
|
$126.14M |
$3.80
+1.06%
|
|
Actinium's therapies use radioactive isotopes linked to targeting biologics, aligning with radioligand therapy modalities.
|
$46.48M |
$1.49
-1.97%
|
|
RADX engages in radioligand therapy via radiolabeled targeting molecules (e.g., Nano-mAbs, small molecules) for cancer treatment.
|
$46.41M |
$7.03
-5.64%
|
|
Direct radioligand therapy modality using radioactive isotopes for targeted cancer treatment (RadioGel).
|
$40.84M |
$0.09
+0.90%
|
|
Operates in radioligand therapy, delivering radioactive payloads to tumors via targeted molecules.
|
$7.13M |
$4.64
-3.73%
|
|
Pursuing radioligand therapy as a cancer treatment modality via PSMA-targeted radiopharmaceuticals.
|
$1.67M |
$3.80
+6.74%
|
|
Radioligand therapy is a therapeutic use of radiopharmaceuticals; aligns with INIS' theranostics products.
|
$518499 |
$0.05
-7.75%
|
Loading industry metrics...
Loading comparison data...
